Friday October 18, 2019
Home Science & Technology Ross Ulbricht...

Ross Ulbricht, creator of Silk Road website, sentenced to life in prison

0
//

screen_shot_2014-07-10_at_02.16.28.si

By NewsGram Staff Writer

Ross Ulbricht, the convicted mastermind behind the infamous Silk Road website, has been sentenced to life in prison by a Manhattan judge.

Silk Road was an online black market where users could anonymously buy drugs, weapons and other illegal goods.

In addition to his prison sentence, Ulbricht has been ordered to pay a massive restitution of more than $183 million.

“The stated purpose [of the Silk Road] was to be beyond the law. In the world you created over time, democracy didn’t exist. You were captain of the ship, the Dread Pirate Roberts,” Judge Katherine Forrest told Ulbricht as reported by Wired.

“Silk Road’s birth and presence asserted that its…creator was better than the laws of this country. This is deeply troubling, terribly misguided, and very dangerous.”

The defence claimed that Ulbricht started Silk Road as an economic experiment, but handed it off to others after a few months. However he was lured back to the site to be set up as a fall guy when prosecutors were closing in.

Vice News reported that Ulbricht’s family is planning to appeal the sentencing.

Next Story

Donepezil, A Drug Used For Alzheimer Disease, Doubles Hospitalisation Risk

Researchers have found that a drug, donepezil commonly used to manage symptoms of Alzheimer disease and other forms of dementia, is associated with a two-fold higher risk of hospitalisation

0
Drugs, Alzheimer, Dementia, Hospitalisation, Risk
Dementia is a growing problem, with almost 10 million newly diagnosed cases every year around the world. Pixabay

Researchers have found that a drug, donepezil commonly used to manage symptoms of Alzheimer disease and other forms of dementia, is associated with a two-fold higher risk of hospitalisation.

According to the study published in the journal Canadian Medical Association Journal (CMAJ), using donepezil increases the risk of hospital admission for rhabdomyolysis, a painful condition of muscle breakdown, compared with several other cholinesterase inhibitors.

Dementia is a growing problem, with almost 10 million newly diagnosed cases every year around the world, said the researchers.

Drugs, Alzheimer, Dementia, Hospitalisation, Risk
Dr. William Burke goes over a PET brain scan, Aug. 14, 2018 at Banner Alzheimers Institute in Phoenix, Arizona. VOA

“The findings of this population-based cohort study support regulatory agency warnings about the risk of donepezil-induced rhabdomyolysis,” said study researcher Jamie Fleet from McMaster University in Canada.

The study, led by researchers at Western University, looked at ICES data from 2002 to 2017 on 2,20,353 patients aged 66 years or older in Ontario, Canada, with a new prescription for donepezil, rivastigmine or galantamine, three cholinesterase inhibitors used to manage dementia and Alzheimer disease.

ALSO READ: Gas-Capturing Capsules To Measure What Gases You Have

The researchers found that donepezil was associated with a two-fold higher risk of hospitalisation for rhabdomyolysis, a serious condition that can result in kidney disease.

According to the findings, the relative risk was small but statistically significant. (IANS)